ImmunoPrecise Antibodies Stock Forecast, Price & News

-0.60 (-8.14 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume44,600 shs
Average Volume93,989 shs
Market Capitalization$129.77 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IPA News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

ImmunoPrecise Antibodies logo

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.00 out of 5 stars

Medical Sector

1937th out of 2,100 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ImmunoPrecise Antibodies (NASDAQ:IPA) Frequently Asked Questions

Is ImmunoPrecise Antibodies a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ImmunoPrecise Antibodies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPA, but not buy additional shares or sell existing shares.
View analyst ratings for ImmunoPrecise Antibodies
or view top-rated stocks.

What stocks does MarketBeat like better than ImmunoPrecise Antibodies?

Wall Street analysts have given ImmunoPrecise Antibodies a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImmunoPrecise Antibodies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 135,200 shares, an increase of 42.3% from the May 13th total of 95,000 shares. Based on an average daily volume of 77,800 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.8% of the company's shares are short sold.
View ImmunoPrecise Antibodies' Short Interest

Who are ImmunoPrecise Antibodies' key executives?

ImmunoPrecise Antibodies' management team includes the following people:
  • Dr. James S. Kuo M.B.A., M.D., Independent Chairman (Age 56)
  • Dr. Jennifer Lynne Bath Ph.D., CEO, Pres & Director
  • Ms. Lisa Helbling, Chief Financial Officer
  • Dr. Yasmina Noubia Abdiche Ph.D., Chief Scientific Officer
  • Dr. Stefan Lang, Chief Bus. Officer
  • Mr. David E. Orton, Chief Operating Officer
  • Ms. Lauren Smith, VP of Marketing and Sales

Who are some of ImmunoPrecise Antibodies' key competitors?

What is ImmunoPrecise Antibodies' stock symbol?

ImmunoPrecise Antibodies trades on the NASDAQ under the ticker symbol "IPA."

Who are ImmunoPrecise Antibodies' major shareholders?

ImmunoPrecise Antibodies' stock is owned by a number of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (2.71%), AWM Investment Company Inc. (2.49%), Ikarian Capital LLC (0.78%), JPMorgan Chase & Co. (0.23%), Credit Suisse AG (0.17%) and Morgan Stanley (0.12%).

Which institutional investors are buying ImmunoPrecise Antibodies stock?

IPA stock was bought by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., Ikarian Capital LLC, Ingalls & Snyder LLC, Credit Suisse AG, JPMorgan Chase & Co., Morgan Stanley, and Rockefeller Capital Management L.P..

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoPrecise Antibodies' stock price today?

One share of IPA stock can currently be purchased for approximately $6.77.

How much money does ImmunoPrecise Antibodies make?

ImmunoPrecise Antibodies has a market capitalization of $129.77 million.

What is ImmunoPrecise Antibodies' official website?

The official website for ImmunoPrecise Antibodies is

How can I contact ImmunoPrecise Antibodies?

The company can be reached via phone at 701 353 0022.

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.